Looking Off-Label: Drug-Eluting Stents Versus Surgery And Bare-Metal
This article was originally published in The Gray Sheet
Executive Summary
Two registry studies reported last week assess outcomes from drug-eluting stent procedures in patients with conditions that are not approved indications for the device. In one, the stents did not match the outcomes of open-heart surgery, but in the other the devices outpeformed their bare-metal cousins
You may also be interested in...
Drug-Eluting-Stent Market Penetration At Nadir? Rebound Forecast At TCT
U.S. drug-eluting-stent market penetration reached an all-time low in September, but clinicians meeting last week in Washington, D.C., are confident new data will help to reverse the trend that began just over a year ago
Off-Label Drug-Eluting Stent Data Weak; Label Should Be Revised – Panel
FDA panel members recommended changes to drug-eluting stent labeling that would more clearly indicate differences between on- and off-label use. However, they found that the data was insufficient to make definitive conclusions about risks for unapproved applications, which account for the majority of stent placements
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.